视网膜Müller细胞释放的外泌体miR-92a-3p通过靶向Notch-1传递白细胞介素-17A信号促进糖尿病视网膜病变
研究探讨IL-17A通过Müller细胞外泌体miRNA传递至视网膜神经节细胞促进糖尿病视网膜病变的机制。体外实验显示IL-17A上调Müller细胞外泌体miR-92a-3p,后者靶向抑制RGCs中Notch-1并增加神经元死亡;链脲佐菌素诱导的糖尿病小鼠玻璃体腔注射IL-17A处理的外泌体可下调视网膜Notch-1并增加RGC凋亡,而miR-92a-3p抑制剂可阻断这些效应。作者认为含miR-92a-3p抑制剂的外泌体玻璃体腔给药可能成为糖尿病视网膜病变的潜在治疗策略。
要点
- IL-17A处理上调Müller细胞来源外泌体中的miR-92a-3p,该效应可被抗IL-17A抗体阻断。
- IL-17A处理的外泌体下调受体RGCs中Notch-1并增加神经元死亡,miR-92a-3p抑制剂可抑制、模拟物可增强这些效应。
- 糖尿病小鼠玻璃体腔注射该外泌体下调视网膜Notch-1并增加RGC凋亡,miR-92a-3p抑制剂可阻断。
核心结论
- Müller细胞释放的外泌体miR-92a-3p通过抑制靶基因Notch-1传递IL-17A信号,加速糖尿病视网膜病变进展。
- 作者认为,玻璃体腔注射含miR-92a-3p抑制剂的外泌体可能成为糖尿病视网膜病变的潜在治疗策略。
研究设计与样本
- 体外研究:原代培养的Müller细胞来源外泌体经高通量测序鉴定差异表达miRNA,双荧光素酶报告基因实验确定miR-92a-3p与Notch-1的靶向关系。
- 体外干预:Müller细胞经高糖、IL-17A、抗IL-17A抗体、miR-92a-3p抑制剂或模拟物处理,其外泌体应用于原代视网膜神经节细胞。
- 动物实验:链脲佐菌素诱导糖尿病小鼠接受玻璃体腔注射。
主要发现
- 在有无高糖条件下,IL-17A处理均上调Müller细胞外泌体中miR-92a-3p表达,该效应被抗IL-17A抗体阻断。
- IL-17A处理Müller细胞来源的外泌体下调受体RGCs中Notch-1表达并增加神经元死亡。
- 上述IL-17A效应被miR-92a-3p抑制剂抑制、被miR-92a-3p模拟物增强。
- 链脲佐菌素小鼠玻璃体腔注射IL-17A处理Müller细胞来源外泌体后,视网膜Notch-1表达下调、RGC凋亡增加,这些效应被miR-92a-3p抑制剂阻断。
临床怎么用
- 作者认为,玻璃体腔注射含miR-92a-3p抑制剂的外泌体可能成为糖尿病视网膜病变的潜在治疗策略。
局限性
- 原文在引言中述及IL-17A影响糖尿病视网膜病变的机制需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Inflammatory processes have been involved in diabetic retinopathy (DR). Interleukin (IL)-17A, a pro-inflammatory cytokine, is associated with DR occurrence and development. However, mechanisms underlying the IL-17A impact on DR need further investigations. Herein, we show that exosomal miRNA delivers IL-17A signal from Müller cells (MCs) to retinal ganglion cells (RGCs) to facilitate DR. METHODS: Exosomes isolated from primarily cultured MCs were identified and high-throughput sequencing was used to indicate differentially expressed miRNAs in the exosomes. Targeting relationship of miR-92a-3p and Notch-1 was determined by dual-luciferase reporter assay. MCs were treated with high glucose (HG), IL-17A, anti-IL-17A antibody, miR-92a-3p inhibitor, or/and miR-92a-3p mimic, and exosomes derived from MCs with the various treatments were applied to primary RGCs. DR mice were induced by streptozotocin (STZ) and subjected to intravitreal injection. RESULTS: Expression of miR-92a-3p in exosomes derived from MCs with IL-17A treatment in either the absence or the presence of HG was upregulated, and the IL-17A effect was blocked by anti-IL-17A antibody. The exosomes derived from IL-17A-treated MCs downregulated Notch-1 expression in recipient RGCs and increased the neuronal death. These effects of IL-17A were suppressed by miR-92a-3p inhibitor but enhanced by miR-92a-3p mimic. In STZ mice, intravitreal administration of exosomes derived from IL-17A-treated MCs downregulated retinal Notch-1 expression and increased RGC apoptosis. These IL-17A effects were hindered by miR-92a-3p inhibitor. CONCLUSIONS: MC-released exosomal miR-92a-3p transmits IL-17A signal by inhibiting the target Notch-1 to accelerate DR progression. An intravitreal administration of exosomes containing miR-92a-3p inhibitor may become a potential therapeutic strategy for DR.
引用
- Qiu AW, Wang NY, Yin WJ, et al. Retinal Müller Cell-Released Exosomal MiR-92a-3p Delivers Interleukin-17A Signal by Targeting Notch-1 to Promote Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2025. PMID: 39745681. doi:10.1167/iovs.66.1.1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。